Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Molecular Cancer Therapeutics is Scopus-indexed (Q1, CiteScore 9.5), WoS SCIE. Published by American Association for Cancer Research Inc..
Checked against the index lists dated .
ISSN 1535-7163Verify ISSN ↗1538-8514Verify ISSN ↗
Publisher: American Association for Cancer Research Inc.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 59 / 428 | 86th | Q1 |
| Cancer Research | 55 / 233 | 76th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2001–present, best quartile Q1, CiteScore 9.5.
Molecular Cancer Therapeutics is Q1 in Oncology (rank 59 of 428) and Q1 in Cancer Research (rank 55 of 233), by CiteScore 2025.
Molecular Cancer Therapeutics is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 9.5, which places it in quartile Q1 at the 86th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.392, quartile Q1, with an H-index of 212.
Molecular Cancer Therapeutics is published by American Association for Cancer Research Inc. Its print ISSN is 1535-7163 and its online ISSN is 1538-8514.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Molecular Cancer Therapeutics has an h-index of 219 and a 2-year mean of 2.14 citations per paper (OpenAlex). Its Scopus CiteScore is 9.5, quartile Q1. On 2-year citations it ranks #181 of 424 Scopus journals in Oncology.
Molecular Cancer Therapeutics published 612 papers in 2025; its busiest recent year was 2018 with 755. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 88 research articles (2026), authors are most often from United States (49.5%), Japan (10.5%) and China (9.7%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 46 retracted papers are recorded (3.6 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.